Afatinib (BIBW2992)

Catalog No.S1011

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Cited by 74 Publications

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )
Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )
Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M33kRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1G5c2lEPTB;MD6wNFU4OiEQvF2=	MXvTRW5ITVJ?
KASUMI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMEC5NVEh\|ryP	NHT1OpFUSU6JRWK=
HCC2218	NYLqbHZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rWcGlEPTB;MD6wNFk5PyEQvF2=	MmXaV2FPT0WU
KARPAS-45	M3jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LhSGlEPTB;MD6wNVY4OSEQvF2=	MmXNV2FPT0WU
HSC-4	M{L5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnWxTWM2OD1yLkCxO\|Q5KM7:TR?=	NULRcVJ[W0GQR1XS
CHL-1	M2fXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TVUmlEPTB;MD6wNVg{QSEQvF2=	MVfTRW5ITVJ?
KY821	NV3UWY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4myfWlEPTB;MD6wNlA3KM7:TR?=	MUPTRW5ITVJ?
NCI-N87	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMEK3O\|Mh\|ryP	M4j3[XNCVkeHUh?=
DOK	M4\Lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMEOxPVQh\|ryP	M{LHfnNCVkeHUh?=
DSH1	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTETWM2OD1yLkCzN\|E1KM7:TR?=	MlLmV2FPT0WU
MDA-MB-175-VII	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEO0NVYh\|ryP	NXS3PXQyW0GQR1XS
NCI-H2170	NU\0TYJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTvTWM2OD1yLkCzO\|I5KM7:TR?=	MWrTRW5ITVJ?
BT-474	M2fSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;ETWM2OD1yLkC0PVg3KM7:TR?=	NGO1NGlUSU6JRWK=
EFO-27	NFT3T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3nUmRKSzVyPUCuNFUyQDJizszN	NI\FfWdUSU6JRWK=
NCI-H720	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj4R4lvUUN3ME2wMlA2OzJ3IN88US=>	M4C0S3NCVkeHUh?=
PC-14	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1K1U2lEPTB;MD6wOVY3QCEQvF2=	NFrJeVNUSU6JRWK=
EC-GI-10	NXnDT3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PafmlEPTB;MD6wOVkyOiEQvF2=	MnjsV2FPT0WU
KYSE-450	NWPUOJJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEW5O\|gh\|ryP	MWXTRW5ITVJ?
BPH-1	NF7WT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMEW5PFgh\|ryP	M{mxTXNCVkeHUh?=
NCI-H292	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUG3UXlnUUN3ME2wMlA3ODlizszN	M1jqPHNCVkeHUh?=
H9	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPXTWM2OD1yLkC3NVMzKM7:TR?=	NF:ySZBUSU6JRWK=
NCI-H526	NXX6fFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvzcploUUN3ME2wMlA4QDJ\|IN88US=>	NH[2T3VUSU6JRWK=
NCI-H1623	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEiwNlUh\|ryP	MmjDV2FPT0WU
KYSE-140	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMEizN{DPxE1?	NEn6fYpUSU6JRWK=
Ca9-22	NYDUXXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGL0NI9KSzVyPUCuNFg{PTNizszN	MlPYV2FPT0WU
AU565	NEfVdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUOzTo5vUUN3ME2wMlA5PTB2IN88US=>	MVTTRW5ITVJ?
ZR-75-30	NXLMNHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEm1OFUh\|ryP	NYfNOpBsW0GQR1XS
NCI-H1770	M4D0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nETGlEPTB;MD6xNFI5KM7:TR?=	Mn;iV2FPT0WU
LB2241-RCC	NYrCUZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMUC4PFQh\|ryP	NW\2Rnp2W0GQR1XS
CAL-39	M4f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XkeWlEPTB;MD6xNVc6OiEQvF2=	NIPNUGNUSU6JRWK=
UACC-893	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTsbW5KSzVyPUCuNVE5QDVizszN	NHnBc\|hUSU6JRWK=
LU-65	NH:ydWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDpTWM2OD1yLkGyOlM{KM7:TR?=	M2rKPHNCVkeHUh?=
HN	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[zNGZKSzVyPUCuNVMxPzdizszN	M361ZnNCVkeHUh?=
TI-73	NWr1Z2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwMUS3NVUh\|ryP	NF7RbWVUSU6JRWK=
KU812	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzidnRKSzVyPUCuNVU1PTZizszN	M1XmbnNCVkeHUh?=
SW13	NFn3XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn0ZpBKSzVyPUCuNVYzOTZizszN	NXH0UGtwW0GQR1XS
BB30-HNC	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMU[1O\|Yh\|ryP	M4\pVnNCVkeHUh?=
HSC-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMU[4N\|ch\|ryP	M2LjUXNCVkeHUh?=
BV-173	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT0[lhKSzVyPUCuNVc2QTZizszN	M3z1Z3NCVkeHUh?=
CAL-27	NVXkWG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvjTWM2OD1yLkG3OlM3KM7:TR?=	M2nKd3NCVkeHUh?=
SBC-1	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTS[pZ2UUN3ME2wMlE5QTV7IN88US=>	Mnq2V2FPT0WU
CAL-33	NHLSbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWriTngxUUN3ME2wMlIxOTh2IN88US=>	NF3URVFUSU6JRWK=
NCI-H209	NEfD[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fMVWlEPTB;MD6yNFQ3KM7:TR?=	NGfDRnNUSU6JRWK=
COR-L105	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TpXGlEPTB;MD6yNVA5PCEQvF2=	NH3kfYdUSU6JRWK=
HSC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\pd40xUUN3ME2wMlIyOTl6IN88US=>	NIn0NZFUSU6JRWK=
NCI-H69	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlqwTWM2OD1yLkKxOFUyKM7:TR?=	NXrqUHFGW0GQR1XS
MOLT-13	NYPnNnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTGTWM2OD1yLkKzPVc2KM7:TR?=	M1rBb3NCVkeHUh?=
ML-2	NIfQXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFKzTpNKSzVyPUCuNlQ5ODJizszN	NV6zd3V4W0GQR1XS
IGROV-1	NF3RWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S4T2lEPTB;MD6yOVk2OiEQvF2=	M1m2[3NCVkeHUh?=
TK10	M37kbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP2Z5R3UUN3ME2wMlI3PzN6IN88US=>	MkDPV2FPT0WU
EoL-1-cell	M4XXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKyTWM2OD1yLkK2PFkzKM7:TR?=	NX\ye3dzW0GQR1XS
HO-1-N-1	M{TMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4e1UWlEPTB;MD6yO\|g2OyEQvF2=	M{naPHNCVkeHUh?=
BHY	NVnrOGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojmTWM2OD1yLkK4OlU2KM7:TR?=	NFLXZ4NUSU6JRWK=
LU-139	NV7BeGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPZbGpJUUN3ME2wMlMxPTFizszN	Mn64V2FPT0WU
23132-87	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33vOmlEPTB;MD6zNVkzOyEQvF2=	NV;0eXYzW0GQR1XS
ACHN	M{LGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzLNWI{UUN3ME2wMlMyQTl2IN88US=>	NETtVIhUSU6JRWK=
DoTc2-4510	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrld3RKSzVyPUCuN\|IzOTlizszN	MWPTRW5ITVJ?
BB65-RCC	NH\HdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:yTWM2OD1yLkO0OVk{KM7:TR?=	NG\0d5NUSU6JRWK=
HLE	NVjOboxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLGNopKSzVyPUCuN\|UxPDZizszN	M3PNNHNCVkeHUh?=
HCC1419	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP4SHpKSzVyPUCuN\|Y1ODhizszN	NIfEe3NUSU6JRWK=
A388	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HUXmlEPTB;MD6zOlg2PyEQvF2=	NF;2fplUSU6JRWK=
NUGC-3	NGPKSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\yT2lEPTB;MD6zPFM4OyEQvF2=	MlLGV2FPT0WU
KYSE-180	NEPme2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzKVo1JUUN3ME2wMlM6ODh7IN88US=>	M1\Yc3NCVkeHUh?=
TE-6	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mke2TWM2OD1yLkSwNlQ3KM7:TR?=	M1PibHNCVkeHUh?=
A498	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\DcW5KSzVyPUCuOFA3PzRizszN	MmL2V2FPT0WU
NCI-H1648	NGTab2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwNESxPFIh\|ryP	M3u3U3NCVkeHUh?=
DU-145	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXu5VXJ2UUN3ME2wMlQ1QDN\|IN88US=>	Mn61V2FPT0WU
CW-2	M3zHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO2RpNKSzVyPUCuOFY6OTRizszN	MoflV2FPT0WU
A431	NYfDOpN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwNEiyN\|Mh\|ryP	M1XYV3NCVkeHUh?=
SAS	M13UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwNEizPVgh\|ryP	NITUTGVUSU6JRWK=
NCI-H2126	NYLVNHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojLTWM2OD1yLkWxPVI3KM7:TR?=	NInjNnFUSU6JRWK=
NCI-H358	NGPEW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PX[GlEPTB;MD61N\|IyKM7:TR?=	NIHSbZVUSU6JRWK=
FADU	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XIdmlEPTB;MD61OFQxPCEQvF2=	MV7TRW5ITVJ?
ACN	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT5[mpKSzVyPUCuOVUxQTRizszN	NELrdGZUSU6JRWK=
HCC70	NGLQRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojVTWM2OD1yLkW3OlYyKM7:TR?=	MV\TRW5ITVJ?
NCI-H1838	NYG4Z2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorPTWM2OD1yLk[wNlk6KM7:TR?=	NUL2cHhGW0GQR1XS
CAL-54	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULGWG0xUUN3ME2wMlYyPjJzIN88US=>	MVLTRW5ITVJ?
NCI-H1975	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mke4TWM2OD1yLk[xO\|I5KM7:TR?=	MlruV2FPT0WU
COR-L88	NHLicXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlq4TWM2OD1yLk[0NVE{KM7:TR?=	NV31UmdPW0GQR1XS
CTV-1	NHfMT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwNkSzPVIh\|ryP	NUPzOIJXW0GQR1XS
EW-18	M4TRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TlSmlEPTB;MD62PFY6QCEQvF2=	MXLTRW5ITVJ?
HCC1806	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\HWmlEPTB;MD62PVY3PiEQvF2=	M1HlcHNCVkeHUh?=
HuP-T4	NWHPO45LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwNkm3OkDPxE1?	MlLxV2FPT0WU
MDA-MB-361	M2\6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XDVmlEPTB;MD63NlY3OiEQvF2=	NXfafYdKW0GQR1XS
NCI-H1573	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnewTWM2OD1yLkezOlMh\|ryP	M{nOWnNCVkeHUh?=
KU-19-19	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULvVlJKUUN3ME2wMlc4PDZ2IN88US=>	NFX1c5FUSU6JRWK=
COLO-678	NFPLXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;qTWM2OD1yLkiwPFM1KM7:TR?=	NYnDbZRQW0GQR1XS
C-33-A	NHPTSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfHRlVpUUN3ME2wMlgyOjl5IN88US=>	NF\oWG9USU6JRWK=
Calu-3	M{j6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwOEG0N\|Qh\|ryP	NGnYWJJUSU6JRWK=
AGS	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVWwbpdiUUN3ME2wMlg{PjR6IN88US=>	NEDLRnJUSU6JRWK=
SCC-25	NFXDcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHqN\|hyUUN3ME2wMlg1OTdzIN88US=>	M{PlUXNCVkeHUh?=
JVM-2	NVzSfII3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3flSGlEPTB;MD64PFI6QSEQvF2=	M1zlbnNCVkeHUh?=
HCE-T	M3zUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTOTWM2OD1yLki4OFI5KM7:TR?=	NGTudIZUSU6JRWK=
ES4	NX7wW2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3GwWGlEPTB;MD65O\|g{PiEQvF2=	M1HPV3NCVkeHUh?=
EKVX	NYLJO4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPMTWpKSzVyPUGuNFExPjRizszN	MonjV2FPT0WU
D-542MG	NVL0ems4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDVTWM2OD1zLkCxNFY1KM7:TR?=	M175[nNCVkeHUh?=
SW1116	NVe2ZVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFwMEGyPFch\|ryP	NH\LS3RUSU6JRWK=
5637	NGjye\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLpd4huUUN3ME2xMlAyPTFizszN	NV;vbog{W0GQR1XS
HT-1376	NHzib\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTFwMEG1NVMh\|ryP	Mni4V2FPT0WU
NB69	M3jqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLX[GRKSzVyPUGuNFI6PDVizszN	NHzkT5hUSU6JRWK=
YKG-1	NWDSfYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rCfmlEPTB;MT6wOVQyQSEQvF2=	NV\RfWNKW0GQR1XS
EW-3	NIe2bXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\zTWM2OD1zLkC3PFg{KM7:TR?=	MY\TRW5ITVJ?
GCIY	NGHsWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnNTWM2OD1zLkC4NVA1KM7:TR?=	NH;QSXFUSU6JRWK=
SK-MES-1	NF\keoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn1TWM2OD1zLkGxOFg4KM7:TR?=	NWT6RWlvW0GQR1XS
PANC-08-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3RTWM2OD1zLkG2OFE3KM7:TR?=	NFfwSXdUSU6JRWK=
SK-NEP-1	M3vXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjGcVlKSzVyPUGuNVc2OTNizszN	M1;pc3NCVkeHUh?=
SW954	NVzqOWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFwMkCyNVQh\|ryP	M4Dj[HNCVkeHUh?=
NCI-SNU-5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DQd2lEPTB;MT6yN\|kh\|ryP	NEPKU2hUSU6JRWK=
SW48	MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\GPWlEPTB;MT6yOVQ{OiEQvF2=	MVrTRW5ITVJ?
HT-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HGOWlEPTB;MT6yPFc2OyEQvF2=	NXe4NY9jW0GQR1XS
ETK-1	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTiUmtUUUN3ME2xMlM4PDV4IN88US=>	MnfXV2FPT0WU
SCC-15	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwM{m0OVEh\|ryP	MXLTRW5ITVJ?
DU-4475	NIDXXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL4T3hKSzVyPUGuOFAyOjFizszN	NYnzZ21XW0GQR1XS
NB5	NWLnXnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zhfmlEPTB;MT60NVMyPyEQvF2=	MlP3V2FPT0WU
CFPAC-1	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFW2T3dKSzVyPUGuOFI1QTNizszN	MWfTRW5ITVJ?
NCI-H630	NUfOXoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf6d5pKSzVyPUGuOFU2QDJizszN	Ml3nV2FPT0WU
NCI-H82	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XRUGlEPTB;MT61OFAxPiEQvF2=	M32xRXNCVkeHUh?=
ECC10	NWT4UXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;WTWM2OD1zLkW1N\|Y6KM7:TR?=	NYn6d2dFW0GQR1XS
K5	NUfzToxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUmwNZB{UUN3ME2xMlU5OzV5IN88US=>	MWDTRW5ITVJ?
ME-180	NXHwWGpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrpTWM2OD1zLk[xNFk3KM7:TR?=	NWOx[Yk{W0GQR1XS
KYSE-410	NUHtelhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvGN3NKSzVyPUGuOlU3PzJizszN	NYruXlhUW0GQR1XS
G-401	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\acVdEUUN3ME2xMlY4PDF\|IN88US=>	NEG1XlRUSU6JRWK=
TGBC24TKB	M4O2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTBTWM2OD1zLk[4NlMh\|ryP	NWrFNXplW0GQR1XS
Detroit562	NGfhPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[4WmlEPTB;MT63NFE2OiEQvF2=	M1XNNnNCVkeHUh?=
OE19	NYfRVWVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv4TIZKSzVyPUGuO\|E2OTJizszN	NVfhR3p[W0GQR1XS
CAKI-1	NUf0WHJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTFwN{iyNVEh\|ryP	NXTId4lLW0GQR1XS
TE-12	NVPSUGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLpN5ZKSzVyPUGuPFA1OTRizszN	M{PvWXNCVkeHUh?=
NCI-H1666	NH;rWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TKT2lEPTB;MT64NFk1QCEQvF2=	MnnRV2FPT0WU
TE-1	NFTObpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\tc2lEPTB;MT64NVQ4PSEQvF2=	NV;1bZlwW0GQR1XS
CAL-12T	NHLvcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPNTWM2OD1zLki4PVQ2KM7:TR?=	NUPIU3NCW0GQR1XS
TE-8	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr0V3hKSzVyPUGuPVE{PzdizszN	MoTNV2FPT0WU
KYSE-270	M1Hpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\kTWM2OD1{LkCyO\|MzKM7:TR?=	NGT0dHFUSU6JRWK=
GMS-10	NIHpcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTJwMEO1NVch\|ryP	MVHTRW5ITVJ?
A2780	NEDkdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXxTWM2OD1{LkC2Nlk1KM7:TR?=	M{n3bnNCVkeHUh?=
OMC-1	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTJwMEixOlkh\|ryP	MkPFV2FPT0WU
LoVo	NYHtcnZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H3V2lEPTB;Mj6xNFc6PyEQvF2=	NGOzUZpUSU6JRWK=
PANC-03-27	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTHTWM2OD1{LkG2OlMyKM7:TR?=	Ml7rV2FPT0WU
MDA-MB-157	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\JTWM2OD1{LkKxPFI5KM7:TR?=	NGCwSmNUSU6JRWK=
CaR-1	M135Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDCNVFIUUN3ME2yMlI5OjhzIN88US=>	NGfxcVVUSU6JRWK=
769-P	NW\5c2hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rDSmlEPTB;Mj6yPVA{PyEQvF2=	MVjTRW5ITVJ?
NB7	NHLVVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rmRWlEPTB;Mj6yPVY4PiEQvF2=	NH7aRolUSU6JRWK=
MKN7	NVTQdYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfCNFlKSzVyPUKuN\|U{OzVizszN	MYXTRW5ITVJ?
NCI-H1048	M4H0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe5VmZjUUN3ME2yMlQ6OTV6IN88US=>	MXvTRW5ITVJ?
RCM-1	M1r2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn1WlhKSzVyPUKuOVI6OzhizszN	MWTTRW5ITVJ?
HT55	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLWVppIUUN3ME2yMlU4OzhizszN	NFTTNXpUSU6JRWK=
HCC1569	M3HTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTJwNUiyPVch\|ryP	MYDTRW5ITVJ?
LXF-289	M4DFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJwNkO1OlUh\|ryP	MXfTRW5ITVJ?
OVCAR-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJwNkexOlch\|ryP	NV3nbml6W0GQR1XS
TE-10	M3niXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;qdmlEPTB;Mj62PFA4QCEQvF2=	MUHTRW5ITVJ?
SNU-C2B	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTJwNki2NVYh\|ryP	MXfTRW5ITVJ?
LB1047-RCC	NWDPd\|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTJwN{S4PFgh\|ryP	NIi3XFhUSU6JRWK=
SN12C	NV;j[5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJwOUG5OlQh\|ryP	M3\JUHNCVkeHUh?=
786-0	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFqzSmxKSzVyPUOuNFY1ODhizszN	NXKzelMxW0GQR1XS
HT-29	MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPGbJNKSzVyPUOuNFc{ODlizszN	NH3Vd3ZUSU6JRWK=
RPMI-7951	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\tTWM2OD1\|LkC3OVkh\|ryP	MkjkV2FPT0WU
NBsusSR	NFP5ZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m0cWlEPTB;Mz6xPFI2PCEQvF2=	MkG5V2FPT0WU
NKM-1	Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTNwMUi3OFQh\|ryP	M2jCTXNCVkeHUh?=
Capan-2	NXjXSZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH22NG9KSzVyPUOuOFY5PzVizszN	NEe1PGRUSU6JRWK=
MKN1	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTNwNEexNFgh\|ryP	NYLEb4ZlW0GQR1XS
OAW-42	NF7uSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXvZ5N2UUN3ME2zMlUxODJ4IN88US=>	M{XhOHNCVkeHUh?=
SKG-IIIa	M1LSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTNwNUKyN\|ch\|ryP	M{jiU3NCVkeHUh?=
no-11	NVPSN5YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrKbFVKSzVyPUOuOVM2PjRizszN	MV3TRW5ITVJ?
NY	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTNwNUO2OVUh\|ryP	M4DFVXNCVkeHUh?=
HEC-1	NGjmVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr4RotMUUN3ME2zMlU5QTVizszN	MYPTRW5ITVJ?
NCI-H441	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nUSmlEPTB;Mz61PVg1OSEQvF2=	NYO3bFRFW0GQR1XS
NCI-H2009	M{jHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnZTZU{UUN3ME2zMlYyOjF4IN88US=>	NFSxVIRUSU6JRWK=
T47D	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTI[G5oUUN3ME2zMlYzOjF5IN88US=>	NY\nZpBRW0GQR1XS
SNU-449	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjvPYRxUUN3ME2zMlY2QDJ4IN88US=>	NGnVdFVUSU6JRWK=
NCI-SNU-1	NXfjPXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTNwNkm3N\|Uh\|ryP	MnXpV2FPT0WU
BT-20	NV75[lVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknRTWM2OD1\|Lk[5O\|k2KM7:TR?=	MYrTRW5ITVJ?
LS-123	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTNwN{SyPFQh\|ryP	NVX1XHo1W0GQR1XS
8305C	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHnWmtKSzVyPUOuO\|U6OTFizszN	NFvqflZUSU6JRWK=
OCUB-M	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnyfpJpUUN3ME2zMlc3OTh5IN88US=>	MULTRW5ITVJ?
KOSC-2	M37pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{izPWlEPTB;Mz64N\|Q2OSEQvF2=	NV\CVVR1W0GQR1XS
NCI-H1693	M2jZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HFWWlEPTB;Mz64OFE5OSEQvF2=	MUDTRW5ITVJ?
TE-9	NWHRVYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTNwOESzPFIh\|ryP	NF:xcZpUSU6JRWK=
MV-4-11	M3ezWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PsdWlEPTB;Mz64O\|k6PCEQvF2=	MorhV2FPT0WU
GAMG	M3fkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNwOUGzNVQh\|ryP	MWDTRW5ITVJ?
KNS-62	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTNwOUS3N\|Eh\|ryP	M1:1ZnNCVkeHUh?=
MC116	M{XLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTxTWM2OD1\|Lkm1OFg6KM7:TR?=	NV;4b2liW0GQR1XS
647-V	NGPuNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTNwOUi0OVIh\|ryP	M2HqOHNCVkeHUh?=
U-87-MG	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInMdIhKSzVyPUSuNVA1QDFizszN	NEnRPXBUSU6JRWK=
RPMI-8226	NHHkTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLkOG1KSzVyPUSuNVE3OzFizszN	MWHTRW5ITVJ?
SW1417	NIXTNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nLUWlEPTB;ND6xNlE1PyEQvF2=	MkLVV2FPT0WU
LAMA-84	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTRwMUewNkDPxE1?	NYDXb\|hpW0GQR1XS
LS-513	NHPURpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkSzTWM2OD12LkOxNlE4KM7:TR?=	NIDFPJlUSU6JRWK=
KLE	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTRwNEC4NVkh\|ryP	NXLv[2c6W0GQR1XS
HCT-116	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Hy[2lEPTB;ND60NVAxPyEQvF2=	MWLTRW5ITVJ?
EPLC-272H	NWi2[WVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLmdnFKSzVyPUSuOFE2OzNizszN	Ml7MV2FPT0WU
KS-1	NUfvW5l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInGNHJKSzVyPUSuOVA5QDlizszN	M4PDeHNCVkeHUh?=
HT-1197	NGfwTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPxN4Y3UUN3ME20MlUzPjZ7IN88US=>	NGKzdIRUSU6JRWK=
LCLC-97TM1	M4P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HoPWlEPTB;ND61N\|Y5PiEQvF2=	Mn7zV2FPT0WU
ES5	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYWyXpNVUUN3ME20Mlg{PzJ\|IN88US=>	NHvVOpZUSU6JRWK=
CTB-1	M2P6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jvfGlEPTB;ND64OFg5KM7:TR?=	NVLlc2xpW0GQR1XS
HL-60	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjIfHBKSzVyPUSuPFY3OTFizszN	NFXMOXVUSU6JRWK=
VM-CUB-1	NYj6b4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTRwOE[4NVkh\|ryP	M176U3NCVkeHUh?=
MEG-01	NELse2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvDSWlNUUN3ME20Mlk6PDB\|IN88US=>	NWXacYxOW0GQR1XS
KYSE-520	M1z4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorDTWM2OD13LkKwPFM6KM7:TR?=	MYrTRW5ITVJ?
HuO-3N1	NVnLdoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe1eVBKSzVyPUWuNlQxPDNizszN	M{XCbnNCVkeHUh?=
SW620	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iyS2lEPTB;NT6yOFk3PCEQvF2=	MY\TRW5ITVJ?
U031	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfGTWM2OD13LkK1OFI1KM7:TR?=	MkDzV2FPT0WU
TE-5	NGWzZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTVwNEC4OUDPxE1?	MoG5V2FPT0WU
NCI-H747	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTVwNEK0O\|Ih\|ryP	M17t[3NCVkeHUh?=
MG-63	M1n5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;jTWM2OD13LkS4O\|YzKM7:TR?=	NWnDUXhVW0GQR1XS
HC-1	NYjCb2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zqeGlEPTB;NT61NVg{QSEQvF2=	NICwTY5USU6JRWK=
HCC2998	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXQdJNKSzVyPUWuOVI3OTVizszN	MWnTRW5ITVJ?
NTERA-S-cl-D1	NYS4c2VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTVwNUS1N\|ch\|ryP	NVzn[YI4W0GQR1XS
KINGS-1	NV7CVFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTVwNkC5OFQh\|ryP	NYizfIRWW0GQR1XS
D-423MG	M4DueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{naTmlEPTB;NT62NVcxPSEQvF2=	M1OyOXNCVkeHUh?=
SW962	NVzIeI1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPDc3lKSzVyPUWuOlIxOzJizszN	MWLTRW5ITVJ?
LOXIMVI	M3zyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknoTWM2OD13Lk[zPFc{KM7:TR?=	MVHTRW5ITVJ?
LS-411N	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PQcGlEPTB;NT63PVQ1OSEQvF2=	MVHTRW5ITVJ?
NCI-H2291	M13aTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PXNmlEPTB;NT65PFk1OyEQvF2=	NYLCd3Q2W0GQR1XS
A549	NEHQZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTZwMUK1OVMh\|ryP	M4DoW3NCVkeHUh?=
LS-1034	NGO4Z\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO5OXFKSzVyPU[uNlA4ODZizszN	MYHTRW5ITVJ?
NB14	NUDRdI46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrVTWM2OD14LkSzPFM3KM7:TR?=	NWKzTHY1W0GQR1XS
NCI-H1299	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfp[lVKSzVyPU[uOlMyPzFizszN	MlS1V2FPT0WU
BT-549	NYPQclhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjvTWM2OD14Lk[2PFg6KM7:TR?=	M3v4PHNCVkeHUh?=
J-RT3-T3-5	M{HLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTZwOE[5JO69VQ>?	MVHTRW5ITVJ?
SW756	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jIeGlEPTB;Nj65NVE4PiEQvF2=	NIjCOZJUSU6JRWK=
DJM-1	M4TVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\ZTWM2OD14LkmyNFEzKM7:TR?=	NFv4bFFUSU6JRWK=
GP5d	M1zoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jWcmlEPTB;Nj65O\|M6PCEQvF2=	Mlj0V2FPT0WU
MOLT-4	M4O5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HZc2lEPTB;Nz6wNlE{PSEQvF2=	NGTrSY5USU6JRWK=
NCI-H28	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHuyS4xKSzVyPUeuNVY1ODVizszN	NGjmT3hUSU6JRWK=
MN-60	NIPCUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXxcoV6UUN3ME23MlI5ODh7IN88US=>	M3fKbnNCVkeHUh?=
RMG-I	NHvyXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\XXZRSUUN3ME23MlM6Ojl4IN88US=>	NE\JW3JUSU6JRWK=
COLO-800	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPiXHRKSzVyPUeuOFE1PDZizszN	NF63S5NUSU6JRWK=
DB	M{Kwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37TeGlEPTB;Nz62NVAxPSEQvF2=	M2L0bnNCVkeHUh?=
Ca-Ski	NGCzVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHBUlFWUUN3ME23MlY1OjV7IN88US=>	MmTyV2FPT0WU
HEL	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzNTWM2OD15LkexNlA{KM7:TR?=	NW\sXFlCW0GQR1XS
NH-12	NXm5PWZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS3[\|lKSzVyPUeuO\|I5ODhizszN	NFjrPWFUSU6JRWK=
LB373-MEL-D	M376Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfRdGtIUUN3ME23Mlc3PzdzIN88US=>	MVXTRW5ITVJ?
SW900	NGHzXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILyfotKSzVyPUeuPFIyOjFizszN	NEPNdGVUSU6JRWK=
JVM-3	NIHvVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjrTGhKSzVyPUeuPFk2QTlizszN	Mmj2V2FPT0WU
OAW-28	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3KSHZFUUN3ME23Mlk1PTd6IN88US=>	NXG0WXRjW0GQR1XS
KURAMOCHI	M376fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPKTWM2OD15Lkm0PFEyKM7:TR?=	MUnTRW5ITVJ?
BE-13	NHnRdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zUOWlEPTB;Nz65PFEyOiEQvF2=	NYTWcnVGW0GQR1XS
VMRC-RCZ	NH7SXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\oeGZKSzVyPUiuNFE3QTdizszN	MkTYV2FPT0WU
NCI-H727	NWnRcGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHnOIZvUUN3ME24MlExPDJizszN	M3\sZ3NCVkeHUh?=
SW1710	M17QSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRThwMUi1NVUh\|ryP	M{PlUHNCVkeHUh?=
D-502MG	M3ztemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPDU\|NKSzVyPUiuNlkzQDJizszN	NUDB[3JSW0GQR1XS
NCI-H1993	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRThwM{O2N\|Eh\|ryP	MWfTRW5ITVJ?
SCC-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES5W3VKSzVyPUiuOFQxPTlizszN	MnraV2FPT0WU
HAL-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7WTnNSUUN3ME24MlUyQTFizszN	NFv5SpZUSU6JRWK=
GT3TKB	NEPqTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGD2cGNKSzVyPUiuOlc6PjRizszN	NUPBfINLW0GQR1XS
SK-OV-3	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRThwN{GzNlkh\|ryP	M3rCUHNCVkeHUh?=
COLO-829	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRThwOEC5O\|Yh\|ryP	M2rNT3NCVkeHUh?=
OCI-AML2	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TJTGlEPTB;OD65OVQ5OSEQvF2=	NELLdodUSU6JRWK=
OS-RC-2	M1r3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7PVFRKSzVyPUmuNFIyQSEQvF2=	Ml3LV2FPT0WU
BFTC-909	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDUS5QzUUN3ME25MlA3Pzl7IN88US=>	Mm\OV2FPT0WU
EW-11	NF7xS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi3UHM2UUN3ME25MlE4PjV\|IN88US=>	MXzTRW5ITVJ?
HCE-4	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonFTWM2OD17LkKxOVU5KM7:TR?=	NY\WNYRTW0GQR1XS
BALL-1	NEDaU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTlwMkG5NFch\|ryP	NID5cXFUSU6JRWK=
SF539	NEDzUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrxcplKSzVyPUmuNlM2PjJizszN	MkK5V2FPT0WU
CAMA-1	NXjQfJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTlwMkixNlgh\|ryP	MljJV2FPT0WU
C32	NGPNXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTlwM{OwOlQh\|ryP	NYTCUpNIW0GQR1XS
NCI-H1703	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe5TWdKSzVyPUmuN\|Q{PzVizszN	NWrabZdzW0GQR1XS
NCI-H1650	NYH4Slg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[zfpJvUUN3ME25MlYxQTR4IN88US=>	MXLTRW5ITVJ?
NCI-H1563	NIf2Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTlwN{[wN\|Eh\|ryP	MVLTRW5ITVJ?
CAL-85-1	M3eyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmf3TWM2OD17Lki3N\|g{KM7:TR?=	M1XMVHNCVkeHUh?=
UM-UC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPuTWM2OD17Lkm1NFMh\|ryP	MlfyV2FPT0WU
BxPC-3	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFyLkC5O\|Ih\|ryP	NW\NZZFHW0GQR1XS
MHH-PREB-1	M1XuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFyLkG5PVkh\|ryP	NV33eIU1W0GQR1XS
DEL	NV23fXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHUTVhPUUN3ME2xNE4{QTR4IN88US=>	MUfTRW5ITVJ?
HuCCT1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TM[mlEPTB;MUCuOlA{OyEQvF2=	NYXVVYd2W0GQR1XS
OVCAR-4	NELLdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTFyLki4N\|Uh\|ryP	NYq5fnBjW0GQR1XS
CAL-72	NHeyWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXPTWM2OD1zMD65N\|kyKM7:TR?=	MmnPV2FPT0WU
HCC1954	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnUSJFFUUN3ME2xNU4xPzV2IN88US=>	MV;TRW5ITVJ?
EFO-21	NWrje2loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PydGlEPTB;MUGuNVA1PSEQvF2=	MW\TRW5ITVJ?
FTC-133	NVuw[mU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHntN21KSzVyPUGxMlE1ODdizszN	M1P6V3NCVkeHUh?=
SK-MEL-24	NWLYdFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHSbFJKSzVyPUGxMlI{PjZizszN	M3;hZXNCVkeHUh?=
UACC-62	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnGzTWM2OD1zMT6yN\|Y5KM7:TR?=	M37NNnNCVkeHUh?=
NCI-H650	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnSxTWM2OD1zMT6yOFE5KM7:TR?=	NFPieJpUSU6JRWK=
ALL-PO	M17TWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvPWVVKSzVyPUGxMlI2OTJizszN	NGTUVnZUSU6JRWK=
T84	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjRW\|RKSzVyPUGxMlM6ODdizszN	NEfK[WpUSU6JRWK=
IST-MEL1	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPETWM2OD1zMT60OVU6KM7:TR?=	MkOxV2FPT0WU
SW626	M2nUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfjRXVSUUN3ME2xNU42PzV3IN88US=>	MYrTRW5ITVJ?
RPMI-2650	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfnNYdKSzVyPUGxMlU5QDVizszN	MkPVV2FPT0WU
MC-IXC	NFLTc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3T3c2lEPTB;MUGuOlczQCEQvF2=	NI\qfXdUSU6JRWK=
HOP-62	M1PXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTFzLk[3OlQh\|ryP	NFXuPJNUSU6JRWK=
NOS-1	NYruUnI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjLTWM2OD1zMT63NVA6KM7:TR?=	M1vNc3NCVkeHUh?=
SW1573	NHzjfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVf4W2F6UUN3ME2xNU44Ojl3IN88US=>	Ml7YV2FPT0WU
WM-115	NGDNSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PxbWlEPTB;MUGuO\|U5QCEQvF2=	NILPWoxUSU6JRWK=
HuO9	NHn0bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfLTWM2OD1zMT64O\|c1KM7:TR?=	M4TxeHNCVkeHUh?=
YAPC	NGPlZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XLNmlEPTB;MUGuPVI2QSEQvF2=	M13UUHNCVkeHUh?=
MDA-MB-453	NE[yV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorPTWM2OD1zMT65OVE2KM7:TR?=	MnLvV2FPT0WU
NCI-H596	NILtU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DYbGlEPTB;MUKuNFM3QSEQvF2=	MVnTRW5ITVJ?
A172	NXfSSXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTJTWM2OD1zMj6wO\|k5KM7:TR?=	M1nBdHNCVkeHUh?=
RS4-11	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7jTWM2OD1zMj6xO\|I2KM7:TR?=	MorQV2FPT0WU
HCC1937	NHzvXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDlOGJKSzVyPUGyMlc2PjRizszN	M3TY[HNCVkeHUh?=
SW837	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTF{LkmwNlgh\|ryP	M{nJOnNCVkeHUh?=
NMC-G1	NW\uc2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnPTYtbUUN3ME2xNk46OjN2IN88US=>	NGLoUWhUSU6JRWK=
PFSK-1	NWn3WGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4H4c2lEPTB;MUOuNFYh\|ryP	NWq4XpRDW0GQR1XS
DBTRG-05MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P4c2lEPTB;MUOuNFY{OiEQvF2=	MXnTRW5ITVJ?
SK-UT-1	NETveXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzpTWM2OD1zMz6xNFg{KM7:TR?=	NGLXPWVUSU6JRWK=
OVCAR-5	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTF\|LkG1PVMh\|ryP	NUTiZWVuW0GQR1XS
8505C	NIXsSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF\|LkKwOlch\|ryP	NI\ZVo1USU6JRWK=
SK-MEL-1	M4\Kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGzTYp[UUN3ME2xN{44OTN3IN88US=>	NUDMV2FJW0GQR1XS
LK-2	NYi5c4tVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Ce2lEPTB;MUOuO\|Y{QSEQvF2=	NFrWb3BUSU6JRWK=
OE33	M2XkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv5e3hKSzVyPUGzMlc5PiEQvF2=	NXzwZZVPW0GQR1XS
Ramos-2G6-4C10	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojxTWM2OD1zND6wNlAzKM7:TR?=	M1TvZnNCVkeHUh?=
EW-13	NGHuVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVewcHhGUUN3ME2xOE4xOzV{IN88US=>	NY\oRlNtW0GQR1XS
NCI-H1793	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHj1PZpKSzVyPUG0MlIxQDdizszN	M37DenNCVkeHUh?=
BHT-101	NXPwWHM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDBN2JKSzVyPUG0MlI1OSEQvF2=	NXPITFZHW0GQR1XS
RKO	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTmZVBKSzVyPUG0MlUxPzVizszN	M1PPN3NCVkeHUh?=
NEC8	NFXFRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTF2LkW0O\|Ih\|ryP	NWS1TIF5W0GQR1XS
PANC-10-05	M4PSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTF2Lk[yOFch\|ryP	MnH6V2FPT0WU
NCI-H2030	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTF2Lk[0OFgh\|ryP	M3TZZnNCVkeHUh?=
C2BBe1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTF2Lke2OEDPxE1?	NHXtVWRUSU6JRWK=
EM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHFNZVXUUN3ME2xOE45PTd4IN88US=>	MV3TRW5ITVJ?
HCC1395	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTF2LkmzN\|gh\|ryP	MlnKV2FPT0WU
A2058	NEPCWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTF3LkC0NFkh\|ryP	NIDndnlUSU6JRWK=
SW1463	M2XaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fTbGlEPTB;MUWuNFQ5PSEQvF2=	NYTlUmNSW0GQR1XS
J82	M3fKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzJc4tKSzVyPUG1MlA2PyEQvF2=	MXnTRW5ITVJ?
CAL-120	M1nvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTF3LkG0OFch\|ryP	NF71XpdUSU6JRWK=
COLO-824	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHsTWM2OD1zNT6xOVc6KM7:TR?=	MXvTRW5ITVJ?
LNCaP-Clone-FGC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEGxS2hKSzVyPUG1MlQzPDhizszN	NF;OUZVUSU6JRWK=
CP66-MEL	M17U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDudIh1UUN3ME2xOU41Pjh6IN88US=>	MXzTRW5ITVJ?
OC-314	NFvh[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSzPXNKSzVyPUG1MlQ4OTRizszN	NV3VNYVpW0GQR1XS
OVCAR-8	NFHwbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfWNWlKSzVyPUG1Mlg5PjFizszN	NUmwd2hJW0GQR1XS
MFE-280	NGPHWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHwTWM2OD1zNj6wOFg5KM7:TR?=	NGK5[HBUSU6JRWK=
MHH-NB-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO4TWM2OD1zNj6wPFM6KM7:TR?=	M4nEdnNCVkeHUh?=
SW1990	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTF4LkG3OVUh\|ryP	MUnTRW5ITVJ?
U-266	NI\1XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTF4LkKyPVkh\|ryP	M3f6SHNCVkeHUh?=
MFM-223	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PtVWlEPTB;MU[uN\|k3PSEQvF2=	M{PSSnNCVkeHUh?=
L-363	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnk[pBlUUN3ME2xOk41PTd5IN88US=>	MmTyV2FPT0WU
MCF7	NE\mPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvsTWM2OD1zNj60O\|I{KM7:TR?=	NX\BOGJxW0GQR1XS
SK-MEL-3	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTF4LkS3PFch\|ryP	NVTGSGR{W0GQR1XS
HH	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDkW5F[UUN3ME2xOk42OTZ{IN88US=>	MnvYV2FPT0WU
no-10	M3PTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n6dWlEPTB;MU[uOlM1OyEQvF2=	Ml65V2FPT0WU
HuP-T3	M3TKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXsTWM2OD1zNj62OVc3KM7:TR?=	MVrTRW5ITVJ?
QIMR-WIL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jiWmlEPTB;MU[uO\|ExPSEQvF2=	MWXTRW5ITVJ?
NCI-H1092	NIHwboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfEXm9KSzVyPUG2Mlg{OTZizszN	Mk\KV2FPT0WU
MZ2-MEL	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF4Lki0NFMh\|ryP	MXnTRW5ITVJ?
ES3	NWTiSppIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;DTWM2OD1zNj65NVM1KM7:TR?=	NFnKSZZUSU6JRWK=
COLO-684	Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\XenlqUUN3ME2xOk46PDd5IN88US=>	Ml\EV2FPT0WU
NCI-H661	NIHNOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvoNXhKSzVyPUG2Mlk3QTRizszN	MmrLV2FPT0WU
CP50-MEL-B	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\4Xo5KSzVyPUG3MlA{PDNizszN	Mkf3V2FPT0WU
NCI-H2405	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPITWM2OD1zNz6xPVc1KM7:TR?=	Mon5V2FPT0WU
U-2-OS	M3jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLETWM2OD1zNz61N\|A4KM7:TR?=	NIHFd\|hUSU6JRWK=
RERF-LC-MS	M2fwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnoZWRKSzVyPUG3MlU2ODhizszN	MXHTRW5ITVJ?
NCI-H2342	M2D2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzLdJFXUUN3ME2xO{42PTdizszN	NE\YN\|dUSU6JRWK=
ES8	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:0TWM2OD1zNz62NFg4KM7:TR?=	M3jRXHNCVkeHUh?=
MOLT-16	NVjjV4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrRTWM2OD1zNz64PVM1KM7:TR?=	M2PWXHNCVkeHUh?=
RH-18	M2nlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTF6LkCwN\|Uh\|ryP	M4T1[XNCVkeHUh?=
D-283MED	NHPSe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3KZZVKSzVyPUG4MlAxQDhizszN	MoPEV2FPT0WU
RCC10RGB	NF\UXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfzTWM2OD1zOD6wOVU6KM7:TR?=	MYDTRW5ITVJ?
NCI-H1437	NH72Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTF6LkG2OFEh\|ryP	NIj3fYpUSU6JRWK=
SW982	M2nEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTF6LkK2O\|Eh\|ryP	MmnFV2FPT0WU
IST-MES1	NGW0VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPRT3g3UUN3ME2xPE41PDJ6IN88US=>	MknyV2FPT0WU
A704	NXjlVo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnUR\|kzUUN3ME2xPE41PzV\|IN88US=>	NFHCRlNUSU6JRWK=
ESS-1	M2PBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXlSJpKSzVyPUG4MlUzODVizszN	NWThZWY5W0GQR1XS
SCH	M3HkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF6Lk[0OVYh\|ryP	NH6xUXhUSU6JRWK=
COLO-320-HSR	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTF6Lke0OkDPxE1?	NFr0SGpUSU6JRWK=
Mo-T	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;VTWM2OD1zOD64NlA1KM7:TR?=	M1nnW3NCVkeHUh?=
Saos-2	M{O4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\tOYRLUUN3ME2xPU4yOTZ{IN88US=>	MoroV2FPT0WU
SW684	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnxW3NKSzVyPUG5MlE{OjZizszN	MWnTRW5ITVJ?
KMOE-2	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37kPGlEPTB;MUmuNlI1OiEQvF2=	MYjTRW5ITVJ?
MMAC-SF	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjGVmpKSzVyPUG5MlI3ODdizszN	MXnTRW5ITVJ?
JAR	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF7LkK5PUDPxE1?	MYDTRW5ITVJ?
SK-MEL-28	M{n3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTF7LkOzOlMh\|ryP	NEXBOYFUSU6JRWK=
KNS-81-FD	NYi4U4QxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\BTWM2OD1zOT61OFY5KM7:TR?=	NULTXGROW0GQR1XS
ES7	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\vS2o2UUN3ME2xPU43Ojl{IN88US=>	M1\aS3NCVkeHUh?=
AsPC-1	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHOTWM2OD1zOT62OFcyKM7:TR?=	MXrTRW5ITVJ?
NCI-H1155	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzSXFl3UUN3ME2xPU44OjN6IN88US=>	M1P6bXNCVkeHUh?=
KYSE-510	NEDV[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTF7Lki3OFgh\|ryP	MYXTRW5ITVJ?
ES1	NUn1eGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jiUmlEPTB;MUmuPVIyOyEQvF2=	M3vOUHNCVkeHUh?=
PC-3	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFracJRKSzVyPUG5Mlk3ODRizszN	NHzYd2JUSU6JRWK=
GCT	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoKyTWM2OD1{MD6zNFI3KM7:TR?=	M{G5eXNCVkeHUh?=
KARPAS-299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\sfWlEPTB;MkCuN\|QzOiEQvF2=	NVH5V2ZJW0GQR1XS
DOHH-2	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfJTWM2OD1{MD61OFY{KM7:TR?=	Mmr0V2FPT0WU
COLO-741	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJyLk[2JO69VQ>?	M2KzcnNCVkeHUh?=
NCI-H1395	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULpT2h7UUN3ME2yNE43Pjl5IN88US=>	NYTDU\|VXW0GQR1XS
HCC1187	NInQcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DVU2lEPTB;MkCuOlc{PCEQvF2=	M1LhV3NCVkeHUh?=
Becker	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfCWY9ZUUN3ME2yNE44OjBzIN88US=>	NWXVOnVlW0GQR1XS
LU-134-A	NGHR[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjvPYpKSzVyPUKxMlExOjZizszN	M4X3cnNCVkeHUh?=
MKN45	M{XsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4SwfGlEPTB;MkGuNVU2OSEQvF2=	MUHTRW5ITVJ?
LC-2-ad	NGPXZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv3TWM2OD1{MT6yO\|I6KM7:TR?=	NX\PcpduW0GQR1XS
EW-24	M3L2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD1TWM2OD1{MT6zPVQ2KM7:TR?=	NGf2VI1USU6JRWK=
SK-N-AS	NYewZld5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4K3NWlEPTB;MkGuPFI4PiEQvF2=	NHnwcG5USU6JRWK=
NCI-H2052	NUP1TId1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXDR3RKSzVyPUKxMlg6PjNizszN	NY\0NFd{W0GQR1XS
A4-Fuk	M3HLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LSUGlEPTB;MkKuNVQyQSEQvF2=	M2CxUnNCVkeHUh?=
NB10	NEXWSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInqZotKSzVyPUKyMlI{PzFizszN	MV7TRW5ITVJ?
CHP-212	NXLT[3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTJ{LkOyNlIh\|ryP	M2frV3NCVkeHUh?=
KM12	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP1[nRKSzVyPUKyMlM2PiEQvF2=	Mkf6V2FPT0WU
JEG-3	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP4OJEzUUN3ME2yNk4{PzhizszN	NGfmPHBUSU6JRWK=
LN-405	NYToXZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nPZmlEPTB;MkKuOVkyOyEQvF2=	Mly1V2FPT0WU
HCT-15	NFzINI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTJ{Lke0OFEh\|ryP	NWr0eVFYW0GQR1XS
MLMA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33KeGlEPTB;MkKuO\|Q4KM7:TR?=	MYLTRW5ITVJ?
GI-1	NYjBbJFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTuXGZKSzVyPUKyMlc3PThizszN	MkjYV2FPT0WU
RT-112	NIjsN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPoTWM2OD1{Mj64OlE3KM7:TR?=	NVP5[YZ7W0GQR1XS
MPP-89	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\kcoNKSzVyPUKyMlg3PjFizszN	MUHTRW5ITVJ?
A3-KAW	NUXZTYlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnj3TWM2OD1{Mz6xNFA{KM7:TR?=	MYPTRW5ITVJ?
KALS-1	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j1[2lEPTB;MkOuNVQyPCEQvF2=	M4\qUHNCVkeHUh?=
SF126	NXLyc5psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn6TWM2OD1{Mz62PVI1KM7:TR?=	MkWyV2FPT0WU
SiHa	M3PSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\6WGlEPTB;MkOuPVMzPyEQvF2=	M3\uSnNCVkeHUh?=
MDA-MB-415	NIHwdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTLUWxKSzVyPUKzMlk1QTlizszN	NGDjZmpUSU6JRWK=
Daoy	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHm5UnNKSzVyPUK0MlEzPiEQvF2=	NFzvbIFUSU6JRWK=
COR-L23	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFe3[IJKSzVyPUK0MlE4PjdizszN	NVvYO4dYW0GQR1XS
KG-1	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXKbYtKSzVyPUK0MlE6OjhizszN	MW\TRW5ITVJ?
L-428	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJ2LkW3PVEh\|ryP	M{ezU3NCVkeHUh?=
NCI-H520	M17HTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJ2Lki4OlEh\|ryP	NWSyeFNkW0GQR1XS
COLO-792	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG3SGJKSzVyPUK1MlI4OzJizszN	M4rTPHNCVkeHUh?=
NB12	M4njWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJ3LkK5OFch\|ryP	NVy2WW5DW0GQR1XS
GAK	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJ3LkK5OlMh\|ryP	NXzKNZY6W0GQR1XS
SW780	NV;JU\|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3SxZmlEPTB;MkWuN\|I3PCEQvF2=	NWCy[2Y3W0GQR1XS
GB-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\6TWM2OD1{NT60NFY6KM7:TR?=	NEPlXWxUSU6JRWK=
P12-ICHIKAWA	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHoWWRCUUN3ME2yOU41Pzh3IN88US=>	NGPlOohUSU6JRWK=
NCI-H1651	M17BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknLTWM2OD1{NT61PVch\|ryP	MnnEV2FPT0WU
KE-37	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvnTWM2OD1{NT63N\|E2KM7:TR?=	NUPMepM4W0GQR1XS
CCRF-CEM	NXXH[ZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPIeG43UUN3ME2yOU46PjdizszN	Ml3oV2FPT0WU
SF295	NFPyRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJ4LkC0NlUh\|ryP	MVrTRW5ITVJ?
G-361	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rjTmlEPTB;Mk[uNVAzPyEQvF2=	NYW2[YlqW0GQR1XS
HOP-92	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTJ4LkGyNlYh\|ryP	MkPOV2FPT0WU
UMC-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTTU4VvUUN3ME2yOk41PTF2IN88US=>	M1XQSnNCVkeHUh?=
IST-SL1	NV3KdYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPiXJZKSzVyPUK2MlY2QTFizszN	NXnzV5VSW0GQR1XS
TE-11	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTJ4Lke3OVIh\|ryP	NXzXcJBNW0GQR1XS
NCI-H1304	M1TUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnpW3AzUUN3ME2yOk46OTB6IN88US=>	MV\TRW5ITVJ?
SJSA-1	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnzXHN{UUN3ME2yO{4xOTd4IN88US=>	NY\zcodHW0GQR1XS
BCPAP	NUXsfY1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXuTWM2OD1{Nz6xN\|ch\|ryP	MVrTRW5ITVJ?
HTC-C3	NVPsRZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJ5LkK1OlEh\|ryP	MYfTRW5ITVJ?
EW-16	NXXaWYVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTrTWM2OD1{Nz6yPVQ4KM7:TR?=	M4fYO3NCVkeHUh?=
HT-144	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETPW5RKSzVyPUK3MlQxOzJizszN	NXLuOFNTW0GQR1XS
MHH-ES-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTjfJRKSzVyPUK3MlQ1PDdizszN	MXvTRW5ITVJ?
T98G	NY\KSVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPHS5VKSzVyPUK3MlU5PDZizszN	NInFR4hUSU6JRWK=
RPMI-8866	NHe2fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJ5Lke1OlIh\|ryP	NXjaNoVHW0GQR1XS
BEN	M2jT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7tcG5KSzVyPUK3Mlg2OTdizszN	MkLCV2FPT0WU
MDA-MB-231	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ6LkK3PVUh\|ryP	NITNNmhUSU6JRWK=
HuH-7	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fqRWlEPTB;MkiuOFAzQCEQvF2=	Mn;IV2FPT0WU
SK-N-FI	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDLVGtKSzVyPUK4MlQ{OyEQvF2=	NWjsVVNOW0GQR1XS
AN3-CA	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknZTWM2OD1{OD60N\|k2KM7:TR?=	NHnHfHRUSU6JRWK=
EGI-1	MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Ta[2lEPTB;MkiuOVkzQCEQvF2=	NGXQO4RUSU6JRWK=
697	NELiTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfSTWM2OD1{OD62N\|MyKM7:TR?=	NGW0[mhUSU6JRWK=
TCCSUP	NVnrTnYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrzbY5zUUN3ME2yPE43PDF6IN88US=>	Moi1V2FPT0WU
GR-ST	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf3TWM2OD1{OD62Olk3KM7:TR?=	MkP3V2FPT0WU
SK-N-DZ	NVu2doVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknWTWM2OD1{OD62PFg2KM7:TR?=	M4PJ[3NCVkeHUh?=
MIA-PaCa-2	M1\UV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fVT2lEPTB;MkiuO\|k2QSEQvF2=	MnvaV2FPT0WU
IGR-1	NVrFTGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XGNWlEPTB;MkiuPFg4PCEQvF2=	MnzCV2FPT0WU
BFTC-905	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NImzWoJKSzVyPUK5MlI4ODVizszN	NIjPXWtUSU6JRWK=
NCI-H1581	M2fTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jzNmlEPTB;MkmuN\|E1PSEQvF2=	MVrTRW5ITVJ?
RD	NUiw[HpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rnNGlEPTB;MkmuOVI{OyEQvF2=	NWHBW5JzW0GQR1XS
SF268	NU[yOlJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnCNFY4UUN3ME2yPU42QTNzIN88US=>	M1foVnNCVkeHUh?=
SHP-77	M3m0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrnW\|RKSzVyPUK5MlYyQDJizszN	NF[4bFBUSU6JRWK=
D-566MG	NH;XSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTJ7LkmzPVMh\|ryP	NH:wNlJUSU6JRWK=
TGBC1TKB	M4\Qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVj3emRsUUN3ME2zNE4yOjN6IN88US=>	M3;FZnNCVkeHUh?=
MEL-HO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnFVGFKSzVyPUOwMlE1OjNizszN	MnroV2FPT0WU
SJRH30	M4PNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m3SGlEPTB;M{CuNlExQCEQvF2=	NUnqe2hRW0GQR1XS
D-336MG	NH;URlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT5N4pRUUN3ME2zNE4zQDl{IN88US=>	NH:wNVJUSU6JRWK=
C3A	M4rnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnqTHFNUUN3ME2zNE4zQTJ5IN88US=>	NVPWbm56W0GQR1XS
Calu-6	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfkPIZtUUN3ME2zNE4zQTZ\|IN88US=>	MVHTRW5ITVJ?
MZ1-PC	M{PzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvnVJZKSzVyPUOwMlM6OyEQvF2=	NXWySmlbW0GQR1XS
KYSE-70	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\iZ2lEPTB;M{CuOVEyPCEQvF2=	NIXnOW9USU6JRWK=
CAPAN-1	NIW1ZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHVTWM2OD1\|MD61NVgyKM7:TR?=	MXLTRW5ITVJ?
DK-MG	NGT2SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTNyLkW0OVYh\|ryP	NWLVeItXW0GQR1XS
SK-HEP-1	NHe4VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTNyLk[zNlYh\|ryP	NV3ubXNMW0GQR1XS
MS-1	M1LKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTxTWM2OD1\|MD64PFg6KM7:TR?=	Ml7RV2FPT0WU
GI-ME-N	NY\aZWluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzZbIFKSzVyPUOxMlA2PzFizszN	NYj1UIcyW0GQR1XS
NCI-H510A	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTNzLkSwNFYh\|ryP	MoHhV2FPT0WU
NB17	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Tpe2lEPTB;M{GuOVE5PSEQvF2=	MkDwV2FPT0WU
639-V	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHQZ\|N7UUN3ME2zNU42OjR\|IN88US=>	NULTfIhNW0GQR1XS
CAL-51	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;4TWM2OD1\|MT61OlY4KM7:TR?=	NG\vT3BUSU6JRWK=
HGC-27	NFLLVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTNzLkW4O\|Mh\|ryP	M2XBUnNCVkeHUh?=
GOTO	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\yTWM2OD1\|MT64OVA3KM7:TR?=	M3LKZnNCVkeHUh?=
ChaGo-K-1	M33pR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTN{LkCwO{DPxE1?	M2nZdnNCVkeHUh?=
RO82-W-1	M2S2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIGxd4hKSzVyPUOyMlE3ODRizszN	MYHTRW5ITVJ?
SH-4	M4DSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFj4Z2VKSzVyPUOyMlE5PThizszN	MnnJV2FPT0WU
A204	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf1T4dKSzVyPUOyMlUxPjlizszN	NXnWZlhJW0GQR1XS
DMS-273	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXxTWM2OD1\|Mj61N\|IzKM7:TR?=	NHv1NopUSU6JRWK=
KGN	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PMTGlEPTB;M{KuOlM{KM7:TR?=	M1jtOnNCVkeHUh?=
SK-MEL-2	M3L4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjiTWM2OD1\|Mj62OVI4KM7:TR?=	NUD6UJI5W0GQR1XS
NCI-H2228	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfOTWM2OD1\|Mj62OlAzKM7:TR?=	NEDwdlZUSU6JRWK=
MKN28	NXTlSIJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37OVmlEPTB;M{KuO\|g{QCEQvF2=	MYPTRW5ITVJ?
H-EMC-SS	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXZNWdKSzVyPUOyMlk3PzhizszN	MVvTRW5ITVJ?
ATN-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jUc2lEPTB;M{OuNVQyPiEQvF2=	NGTyPZNUSU6JRWK=
D-263MG	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfmTJhKSzVyPUOzMlg{PzhizszN	NEDW[4RUSU6JRWK=
LU-135	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrzcFRKSzVyPUOzMlg5OjlizszN	MV;TRW5ITVJ?
C8166	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjHOlFiUUN3ME2zN{45QDV2IN88US=>	MkTPV2FPT0WU
T-24	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Hic2lEPTB;M{SuNFIxPSEQvF2=	M1jrZXNCVkeHUh?=
Mewo	NIntV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrlWYNwUUN3ME2zOE4yOzR7IN88US=>	MkPKV2FPT0WU
22RV1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWW1fZh2UUN3ME2zOE4yPzV2IN88US=>	MoG4V2FPT0WU
KM-H2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nOZmlEPTB;M{SuNVc4QSEQvF2=	NWjhPIJEW0GQR1XS
NCI-H2122	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TxeWlEPTB;M{SuN\|Q4OSEQvF2=	MWnTRW5ITVJ?
ABC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;jfWlEPTB;M{SuN\|Y6OyEQvF2=	NX:3fnRLW0GQR1XS
NCI-H1355	NXK1NXViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHDNHlKSzVyPUO0MlM5QDlizszN	NXvrSJh5W0GQR1XS
NOMO-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3vSmNyUUN3ME2zOE42PzB\|IN88US=>	MWPTRW5ITVJ?
MZ7-mel	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLk[JVDUUN3ME2zOE43PDh5IN88US=>	NYrx[WxLW0GQR1XS
NCI-H810	M1TCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTN2LkeyO\|gh\|ryP	NXO1[4g3W0GQR1XS
D-392MG	NH61UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XafWlEPTB;M{WuNFU3PSEQvF2=	M123UHNCVkeHUh?=
LB771-HNC	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\FU4xoUUN3ME2zOU4yPjV6IN88US=>	M1HySXNCVkeHUh?=
COLO-679	NI\pdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PYXWlEPTB;M{WuN\|g5KM7:TR?=	MmXhV2FPT0WU
SK-PN-DW	Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrCS3R1UUN3ME2zOU41OzZ7IN88US=>	M3OwdXNCVkeHUh?=
VA-ES-BJ	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7ETWM2OD1\|NT60OlQ6KM7:TR?=	MVvTRW5ITVJ?
KNS-42	NIftRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX6TWM2OD1\|NT61PFI3KM7:TR?=	NIDpWZJUSU6JRWK=
RVH-421	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET2dmVKSzVyPUO1Mlc3PDVizszN	MU\TRW5ITVJ?
P30-OHK	M3Wybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nwUWlEPTB;M{WuPFc2OiEQvF2=	MXHTRW5ITVJ?
G-402	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLsTWM2OD1\|NT65PFY4KM7:TR?=	M1\yd3NCVkeHUh?=
S-117	M1jJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTN4LkOwNFgh\|ryP	MoqwV2FPT0WU
RXF393	NG\4OmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XE[GlEPTB;M{[uN\|c5PSEQvF2=	NXmzSHFOW0GQR1XS
LCLC-103H	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW1TWM2OD1\|Nj63PFA{KM7:TR?=	NIPGNmZUSU6JRWK=
U-118-MG	M3HjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC0dng2UUN3ME2zOk45QDR5IN88US=>	MojnV2FPT0WU
8-MG-BA	M2jVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF24ZYNKSzVyPUO2Mlk1QDNizszN	NX\v[4R7W0GQR1XS
MFH-ino	NHG1RoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7xTWM2OD1\|Nz6zN\|cyKM7:TR?=	Mlz1V2FPT0WU
NCI-H23	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTN5LkSxPVYh\|ryP	M1zwWnNCVkeHUh?=
NCI-H446	NHHTOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPmbXFKSzVyPUO3MlQ5PjJizszN	MUfTRW5ITVJ?
LU-99A	NIT1UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M124b2lEPTB;M{euOVc{OSEQvF2=	MlLrV2FPT0WU
KP-N-YN	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTN5Lk[xPVUh\|ryP	MYrTRW5ITVJ?
SCC-9	NXfDNGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTN5Lke4N\|gh\|ryP	NXXZWHViW0GQR1XS
EFM-19	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fOemlEPTB;M{euO\|k3PyEQvF2=	MljTV2FPT0WU
A427	NWXzOXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;BTWM2OD1\|Nz65NVA4KM7:TR?=	Mn\nV2FPT0WU
LB831-BLC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmGzTWM2OD1\|OD62NFM6KM7:TR?=	MWnTRW5ITVJ?
HOS	NVvycpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PQ[mlEPTB;M{muOlI4OyEQvF2=	NFfvdWFUSU6JRWK=
LAN-6	NGX0SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M162c2lEPTB;NECuNFEyOiEQvF2=	M3z4TnNCVkeHUh?=
U251	NYCybZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HsO2lEPTB;NECuOFA2PCEQvF2=	NFHucnlUSU6JRWK=
SNU-387	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTRyLkS1OVMh\|ryP	MnzaV2FPT0WU
DMS-79	NE[zW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PxVmlEPTB;NECuOVg5QSEQvF2=	M1r4[HNCVkeHUh?=
SK-LU-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe3SJBKSzVyPUSwMlY2PjhizszN	MonUV2FPT0WU
HT	M{jUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPNTWM2OD12MD62OlM6KM7:TR?=	NVj6[G9nW0GQR1XS
KP-N-YS	NULY[3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHk[XpKSzVyPUSwMlY4PjhizszN	M4W2b3NCVkeHUh?=
DMS-114	M2[weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXUN5BKSzVyPUSwMlg{PzRizszN	NUPBcVlvW0GQR1XS
HUTU-80	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmKyTWM2OD12MT6wOVY6KM7:TR?=	NE\YZmFUSU6JRWK=
ONS-76	M3;rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X1dmlEPTB;NEGuOFcxQSEQvF2=	MYLTRW5ITVJ?
A673	NUTaSlB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz1TWM2OD12MT61NVU4KM7:TR?=	NUPnTYx5W0GQR1XS
HPAF-II	NFfWNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTRzLk[3NFkh\|ryP	MVnTRW5ITVJ?
UACC-257	NFO1W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL4[VdXUUN3ME20NU44OzZ7IN88US=>	M3SyT3NCVkeHUh?=
EW-22	NIG1WI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[1S5VKSzVyPUSxMlg3QTdizszN	MoDuV2FPT0WU
NCI-H1755	NUXuUolMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTRzLki3NlUh\|ryP	MUnTRW5ITVJ?
KYSE-150	NVjnWmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTR{LkG3PFIh\|ryP	NXXkbno4W0GQR1XS
CGTH-W-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3OyZmlEPTB;NEKuOFk2PSEQvF2=	MWDTRW5ITVJ?
NB13	M1:yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrzSXBKSzVyPUSyMlYzOTdizszN	NF3XcFhUSU6JRWK=
SW872	NIrySnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVznTIZJUUN3ME20Nk43OzNzIN88US=>	MlL0V2FPT0WU
KP-4	NFGwcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrYTWM2OD12Mj64PFMzKM7:TR?=	NHHmZnNUSU6JRWK=
HCC38	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTR{Lkm2NVgh\|ryP	M{\OcXNCVkeHUh?=
BB49-HNC	NX7LSlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XBdmlEPTB;NEOuNlM2PiEQvF2=	NFLFdZZUSU6JRWK=
CAL-62	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfBUJRKSzVyPUSzMlQxOjhizszN	M{\FbXNCVkeHUh?=
NCI-H2029	NVzNcIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrWbIFmUUN3ME20N{42PThzIN88US=>	MXnTRW5ITVJ?
M14	NUfLTZFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPmWWJFUUN3ME20OE4yOzN{IN88US=>	NFq0[WZUSU6JRWK=
COLO-680N	M{\CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjR[HJKSzVyPUS0MlM{QSEQvF2=	NGHEcVJUSU6JRWK=
Hs-578-T	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37FPGlEPTB;NEWuNFI6PCEQvF2=	MXvTRW5ITVJ?
MSTO-211H	NEKxe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTR3Lkm0PFIh\|ryP	MWnTRW5ITVJ?
EW-1	NWHHVYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTR3Lkm2PFkh\|ryP	MXXTRW5ITVJ?
SW948	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHYWmJKUUN3ME20Ok41PDZ{IN88US=>	M2f1RnNCVkeHUh?=
NCI-H460	NUnjRW9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUiwR4lGUUN3ME20Ok42OjNizszN	MkHIV2FPT0WU
CAS-1	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr3TWM2OD12Nj63O\|AyKM7:TR?=	MY\TRW5ITVJ?
TGBC11TKB	M1jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe5UodKSzVyPUS3MlE4PzdizszN	M2\DOHNCVkeHUh?=
HD-MY-Z	NHvYSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PM[WlEPTB;NEiuO\|g3KM7:TR?=	MUDTRW5ITVJ?
NCI-H226	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfuWXNsUUN3ME20PU44Pzh3IN88US=>	M331NnNCVkeHUh?=
PA-1	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofETWM2OD12OT64N\|M2KM7:TR?=	NXXMR4xNW0GQR1XS
LB2518-MEL	NGTZUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7rXXpQUUN3ME20PU45PzJ\|IN88US=>	MY\TRW5ITVJ?
A101D	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPqTWM2OD12OT65OFI2KM7:TR?=	NHzFRVlUSU6JRWK=
NCI-H2087	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTR7Lkm2PFIh\|ryP	MkjYV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells.	25537503 26052929
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	+ Expand Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03827070	Recruiting	Non Small Cell Lung Cancer	Center Trials & Treatment Europe\|Center Trials & Treatment	March 5 2019	Phase 1
NCT03827070	Recruiting	Non Small Cell Lung Cancer	Center Trials & Treatment Europe\|Center Trials & Treatment	March 5 2019	Phase 1
NCT03727724	Active not recruiting	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Boehringer Ingelheim\|Merck Serono International SA	December 4 2018	Phase 2
NCT03727724	Active not recruiting	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Boehringer Ingelheim\|Merck Serono International SA	December 4 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products4

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 74 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 74 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)